Director's Dealings

ABCAM PLC

("Abcam" or "the Company")

Director's Dealings

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue,was notified on 10 May 2011 that, on the same day, Jeff Iliffe, an Executive Director of the Company, exercised share options over 213,000 ordinary shares of 0.2 pence each in the Company ("Ordinary Shares") at an exercise price of 62.4 pence per share.

Of these, he sold 200,000 Ordinary Shares at a price of 393p per Ordinary Share, retained 10,000 Ordinary Shares and transferred 3,000 Ordinary Shares to his wife, Keren Williams. Following these transactions, Mr Iliffe's total beneficial interest in the Company is 15,960 Ordinary Shares, representing approximately 0.01 percent of the current issued share capital of the Company. 

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 72,000 products, most of which are antibodies, from over 250 suppliers and employs 290 staff.